■ Focus on New Third Banchuan Enterprises
July 22, 2019, is destined to be a memorable day for my country’s multi-level capital market. On this day, the Science and Technology Innovation Board will officially open, and the first batch of 25 companies will take the lead. Although there are no Sichuan companies among them, many Sichuan companies, especially those that are currently or have been listed on the New OTC Market, are still eager to try. Not only are they preparing to transfer to the Science and Technology Innovation Board, but they will also transfer to other sectors for listing based on their actual conditions. After combing through, reporters from the "Financial Investment News" found that among the New Third Board Sichuan Enterprises, Yuandong Biotech and Baiyu Pharmaceutical have submitted applications for listing on the Science and Technology Innovation Board to the Shanghai Stock Exchange; Junyi Digital, which was originally planning to be listed on the GEM, has adjusted its listing plan. It may be listed on the Science and Technology Innovation Board instead; Hainuoer submitted an application for listing on the GEM to the China Securities Regulatory Commission and was accepted; in addition, many companies such as Zilu Palace are also ready to go.
■ Reporter Yang Chengwan
Science and Technology Innovation Board Yuandong Biotech was inquired by the Shanghai Stock Exchange
Yuandong Biotech has made new progress in its sprint towards the Science and Technology Innovation Board. The company received inquiries from the Shanghai Stock Exchange on July 17. The company is sponsored by CITIC Securities, with Beijing Guofeng Law Firm providing legal services, and Zhonghui Accounting Firm (Special General Partnership) providing accounting and auditing services. The company has ceased listing on the New Third Board since April 12, 2017.
Fundamentals show that the company is based on high-end chemical drugs, focusing on innovative drugs, and developing biological drugs. The company has established 2 R&D institutions and 1 biopharmaceutical R&D company, covering the research and development of chemical raw materials, chemical preparations and biological drugs. The chemical pharmaceutical preparation R&D center is set up in Yuandong Biotechnology, the chemical raw material pharmaceutical R&D department is set up in the subsidiary Aoki Pharmaceutical, and the subsidiary Yoluo Biotechnology is responsible for the implementation of biological drug research and development. The company's R&D center has been recognized as the Sichuan Provincial Enterprise Technology Center, and it has also established the Yuandong Biological Branch of the Chengdu High-tech Zone Postdoctoral Research Workstation. In 2018, the company's R&D expenses reached 124 million yuan, accounting for 1.618% of operating income.
The company insists on independent research and development of core technologies, and at the same time cooperates with well-known domestic and foreign scientific research institutes and qualified CRO companies in some research and development processes. The company has established a complete set of mechanisms for screening, evaluation, and control of cooperative institutions to ensure efficient project cooperation results.
The company has a total of 187 R&D personnel, accounting for 28.9% of the company's total number of employees; including 2 Sichuan Province Thousand Talents Plan experts, 2 Chengdu Talent Plan experts, and 70 master/doctoral degree personnel, accounting for 28.9% of the company's total R&D personnel. 37.4, and the proportion of people with a bachelor’s degree or above in medicine majors reaches 86. The company's relevant R&D team was rated as "Innovative Drug R&D Team in Major Disease Fields" in Sichuan Province. The company has 6 core technical personnel and has hosted multiple R&D projects.
Baiyu Pharmaceutical has submitted an application for IPO on the Science and Technology Innovation Board to the Shanghai Stock Exchange. The company was established in 2005 and was listed on the New Third Board in 2016. It will cease to be listed on the New Third Board at the end of June 2017. The company is a modern traditional Chinese medicine enterprise focusing on cardiovascular and cerebrovascular diseases, resistance to infectious diseases, neurological diseases and other fields. In the past three years, it has invested nearly 200 million yuan in R&D, and has 24 drug production approvals, 22 drug clinical approvals, and more than 50 products under development. Among them, Ginkgolide Injection is the first new traditional Chinese medicine injection approved since the implementation of the New Drug Registration Management Measures in 2007, with more than 99 active ingredients.
GEM Hainuoer’s listing application was accepted
Hainuoer was listed on the New Third Board on November 2, 2015. Since 2017, the company has stayed in the innovation layer for three consecutive years. The company's listing direction is the GEM. On June 20 this year, the company submitted an application for an initial public offering of shares and listing on the GEM to the China Securities Regulatory Commission, which has been accepted by the China Securities Regulatory Commission. The company also submitted an application to the National Equities Exchange and Quotations to suspend the transfer of the company's shares.
It is worth noting that on July 11, Junyi Digital announced that after careful study and prudent decision-making, the company planned to adjust its listing plan and apply to the China Securities Regulatory Commission to withdraw its listing application materials. It is reported that on January 7 this year, the company submitted to the Sichuan Securities Regulatory Bureau its planned initial public offering of stocks on the Shenzhen Stock Exchange GEM and listing guidance filing materials. It planned to issue 25.8 million shares, accounting for 25.10 of the company's total share capital after the issuance. The Sichuan Supervision Bureau made an announcement on its official website on January 8 this year. The company is currently receiving coaching from Hualin Securities.
Junyi Digital was listed on the New Third Board on March 28, 2016, and is still listed on the New Third Board. During the listing period, it completed a private placement, raised 45 million yuan, and paid dividends twice. However, in order to cooperate with the transfer of listing, the company's stock transfers will be suspended on the New Third Board market starting from May 29 this year. "It is certain that we will continue to pursue the path to listing, and we do not rule out transferring to the Science and Technology Innovation Board. However, there is no accurate news to confirm it yet." An industry insider said.
Junyi Digital’s main business is to use the Internet of Things, cloud computing, big data, BIM and other new generation smart city application technologies to provide customers with customized development of application software and integration of intelligent and information systems. A comprehensive solution for the smart city industry that integrates services. In 2018, it achieved operating income of 318 million yuan and net profit of 55.2211 million yuan.
Many companies on the New Third Board receive listing guidance
While a few companies have caught up with the "first train" of the Science and Technology Innovation Board, most companies are making their main businesses bigger and stronger. , standardize the company's operations, and actively seek opportunities to transfer boards. The first one to bear the brunt is Zilu Palace, which will continue to stay in the innovation layer this year. It is listed as a "Guidance Registration Enterprise" by Sichuan Province. The company has 2 subsidiaries, 3 production bases, 98 production approval documents, and 4 new drug certificates. The company adopts two sales models: agency and investment promotion, supplemented by professional academic promotion. In 2018, it achieved operating income of 277 million yuan and net profit of 42.3624 million yuan.
Sichuan Weihong, which is also listed as a "Guidance Registration Enterprise" by Sichuan Province, relies on the rich local land, forests and water resources in Qingchuan County and adopts a cooperative planting model of "company base farmers" to engage in edible fungi R&D, planting, production, processing and sales. In 2018, it achieved operating income of 122 million yuan and net profit of 24.568 million yuan.
Laoken Medical is also a "counseling registration enterprise" in Sichuan Province. It is mainly engaged in the research and development, production and sales of hospital infection control equipment, and provides hospitals with overall solutions for disinfection supply centers (CSSD) and disinfection and sterilization outsourcing services. and pharmacy automation overall solutions. In 2018, it achieved operating income of 246 million yuan and net profit of 6.0674 million yuan.
In addition, as a "counseling registration enterprise" in Sichuan Province, Jing Yunxiang has first-level industry access qualifications for general contracting of communications engineering construction and a number of patented technologies, serving China Tower, China Mobile, and China Telecom. , China Unicom provides a series of services including system integration of communication engineering, production and supply of communication equipment, comprehensive maintenance of communication systems, and leasing of communication facilities. In 2018, it achieved operating income of 630 million yuan and net profit of 8.8979 million yuan.
Dexin Technology, which is engaged in the research and development, production and sales of digital TV and audio broadcast front-end and transmission systems, and emergency broadcast systems, is also a "Guidance Registration Enterprise" in Sichuan Province. The company implements full-process quality management from market research, R&D project establishment, R&D design implementation to product promotion. In 2018, it achieved operating income of 229 million yuan and net profit of 50.5325 million yuan.